Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.
Also called NCT07908082
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 120 participants
- Registry
-
NCT07908082
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07908082. Randomized; quadruple masking; primary purpose prevention. Start 2027-10 (anticipated); primary completion 2030-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
- Acronym
- ASPIRE-GCA
- Condition
- Giant Cell Arteritis (GCA)
- Condition
- Acute Coronary Syndrome (ACS)
- Condition
- Ishemic and Thrombotic Complications
- Intervention (Drug)
- Acetyl Salicylic Acid (ASA)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Record details
- Record id
cardio:ct-nct07908082- Content hash
6506f52ae5e93218e4db98ff8b5c233dae5d10fb47ecc6c0bd9761fd45ab3ebd